Evidence map›Paper›PMID 38362425›Full record

ArticleChemical science2024

Enantioselective nickel-catalyzed Mizoroki-Heck cyclizations of amide electrophiles.

Ana S Bulger, Daniel J Nasrallah, Arismel Tena Meza, Neil K Garg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ana S BulgerDepartment of Chemistry and Biochemistry, University of California at Los Angeles Los Angeles California 90095 USA neilgarg@chem.ucla.edu.ORCID https://orcid.org/0009-0005-4363-9941
Daniel J NasrallahDepartment of Chemistry and Biochemistry, University of California at Los Angeles Los Angeles California 90095 USA neilgarg@chem.ucla.edu.ORCID https://orcid.org/0000-0001-8010-6953
Arismel Tena MezaDepartment of Chemistry and Biochemistry, University of California at Los Angeles Los Angeles California 90095 USA neilgarg@chem.ucla.edu.ORCID https://orcid.org/0000-0002-4060-2263
Neil K GargDepartment of Chemistry and Biochemistry, University of California at Los Angeles Los Angeles California 90095 USA neilgarg@chem.ucla.edu.ORCID https://orcid.org/0000-0002-7793-2629

Funding

Exploiting Unconventional Building Blocks in Chemical SynthesisR35GM139593 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Neil K. Garg · 2021 to 2026
$4.0M
NMR Console and Prodigy CryoProbeS10OD028644 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARG, NEIL K · 2021 to 2021
$600k
Time-of-Flight Mass Spectrometer for Synthesis Supporting Biomedical ResearchS10RR025631 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOUK, KENDALL N · 2009 to 2009
$328k
Enantioselective Reactions with Amide Electrophiles Utilizing Transition-Metal CatalysisF31GM149161 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TENA-MEZA, ARISMEL · 2023 to 2025
$86k
NCRR NIH HHS S10 RR025631NIGMS NIH HHS F31 GM149161NIGMS NIH HHS R35 GM139593NIH HHS S10 OD028644
6 · The paper itself

Abstract

Amide cross-couplings that rely on C-N bond activation by transition metal catalysts have emerged as valuable synthetic tools. Despite numerous discoveries in this field, no catalytic asymmetric variants have been disclosed to date. Herein, we demonstrate the first such transformation, which is the Mizoroki-Heck cyclization of amide substrates using asymmetric nickel catalysis. This proof-of-concept study provides an entryway to complex enantioenriched polycyclic scaffolds and advances the field of amide C-N bond activation chemistry.

Identifiers

PMID38362425
PMCPMC10866352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.